North America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The North America Oral Anti-Diabetic Drug Market is segmented into drugs (Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 receptor agonists, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, and Meglitinides), and Geography (United States, Canada and Rest of North America) The report offers the value (in USD million) and volume (in Units million) for the above segments.

North America Oral Anti-Diabetic Drug Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

North America Oral Anti-Diabetic Drug Industry Overview

The North American oral anti-diabetes drug market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Sanofi, and Janssen Pharmaceuticals having a global market presence. In contrast, the remaining manufacturers are confined to the other local or regional markets. Companies are focusing on innovations in diabetes drugs.

North America Oral Anti-Diabetic Drug Market Leaders

  1. Sanofi

  2. Eli Lily

  3. Janssen Pharmaceuticals

  4. Ascencia

  5. Astrazeneca

  6. *Disclaimer: Major Players sorted in no particular order
North America Oral Anti-Diabetic Drug Market Concentration

North America Oral Anti-Diabetic Drug Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?